

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 13th February, 2024

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sardaproteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and nine months ended on 31st December, 2023 and Limited Review Report on Unaudited Financial Results for the quarter and nine months ended on 31st December, 2023.

You are requested to kindly take the same on record.

Thanking You,
Yours Faithfully

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD

Company Secretary

AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M. NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)

Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com



S K AGARWAL & ASSOCIATES

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

LIMITED REVIEW REPORT

UNAUDITED STANDALONE QUARTERLY RESULTS

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and 9 month ended on 31st December, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C

CA Sushil Kumar Agarwal
Partner
M. No.: 403073
UDIN : 24403073BKASIW6327
Place : Bhiwadi
Date : 13.02.2024



SARDA PROTEINS LTD

Reg. Off: H-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
 Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
 CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER 2023


S. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue from Operations	99.99	-	226.50	123.57	505.71	579.52
II	Other Income	4.21	4.13	4.28	12.43	11.93	15.98
III	Total Income (I+II)	104.20	4.13	230.78	136.00	517.64	595.50
IV	Expenses						
	Cost of Material Consumed		-	-	-	-	-
	Purchase of Stock-in-Trade	97.07	-	224.84	120.70	500.41	571.77
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)		-	-	-	-	-
	Employee Benefit Expenses	3.65	2.62	3.62	9.01	10.37	13.48
	Finance Cost		-	-	-	-	-
	Depreciation and Amortisation Expenses		-	-	-	-	-
	Other expenses	2.79	2.02	2.15	6.36	6.20	8.96
	Total Expenses (IV)	103.51	4.64	230.61	136.07	516.98	594.21
V	Profit(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	0.69	(0.51)	0.17	(0.07)	0.66	1.29
VI	Exceptional Items		-	-	-	-	-
VII	Profit(Loss) before Tax (V-VI)	0.69	(0.51)	0.17	(0.07)	0.66	1.29
VIII	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	4.60
IX	Profit(Loss) for the period from Continuing Operations (VII-VIII)	0.69	(0.51)	0.17	(0.07)	0.66	(3.31)
X	Profit(Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax Expenses of Discontinued Operations		-	-	-	-	-
XII	Profit(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit(Loss) for the Period (IX+XII)	0.69	(0.51)	0.17	(0.07)	0.66	(3.31)
XIV	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	0.69	(0.51)	0.17	(0.07)	0.66	(3.31)
XVI	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVII	Earnings per Equity Share						
	(1) Basic	0.04	(0.03)	0.01	(0.00)	0.04	(0.19)
	(2) Diluted	0.04	(0.03)	0.01	(0.00)	0.04	(0.19)

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 13th February 2024
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products"
4. No Investor Complaints were received during the quarter ended 31-Dec-2023 nor any pending as on 01-Jan-2024

CA Sushil Kumar Agarwal
 M.No. 403073
 FRN 014841C
 UDIN: 244030738KASIW6327

Place Jaipur
 Date: 13 Feb 2024



on behalf of the Board
 Sarda Proteins Ltd

Deepak Datta (DIN: 01672415)
 Managing Director